Dermatology
Latest News
Autoimmune Skin Diseases Linked To Risk Of Adverse Pregnancy Outcomes
The three most common autoimmune skin diseases in the study cohort were vitiligo (30%), alopecia areata (30%), and cutaneous lupus erythematosus (...
Latest News
Isotretinoin users do not have higher suicide risk: meta-analysis
The analysis showed that the 1-year absolute risk from between two and eight studies of suicide attempts, suicidal ideation, completed suicides,...
Latest News
Dietary supplements may play a role in managing vitiligo
Overall, there is a “paucity of large, high-quality trials for [complementary] therapies for vitiligo,” said Ammar Ahmed, MD.
News
FDA warns of potentially lethal reaction to seizure meds
Diagnosis is often difficult because early signs and symptoms, such as fever and swollen lymph nodes, may be present without evidence of a rash....
Latest News
New consensus guide on rare drug hypersensitivity reaction
To support clinicians in diagnosing and managing DRESS, a steering committee conducted a literature review to examine current research, identify...
Latest News
Laser epilation may reduce pilonidal disease recurrences when added to standard care
The study is “the first, to our knowledge, to compare LE as an adjunct to standard care versus standard care alone and demonstrate a decrease in...
Latest News
Nail psoriasis in Black patients often overlooked
Clinical training might explain the delay in diagnosis of nail psoriasis in patients with darker skin types.
Latest News
At 52 weeks, complete hair regrowth rates still climbing on deuruxolitinib
Complete responses continued to increase in open-label extensions of phase 3 alopecia areata studies.
Latest News
Tapinarof effective for AD in patients as young as 2 years
Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.
Latest News
Hidradenitis suppurativa: Two anti-IL17A/F therapies yield positive results
Two biologics that inhibit both IL-17A and 17F effectively controlled hidradenitis suppurativa in phase 3 trials.
Latest News
Lebrikizumab gets European nod for treating moderate-to-severe atopic dermatitis
Lebrikizumab remains under review in the United States.